This page shows the latest Myovant Sciences news and features for those working in and with pharma, biotech and healthcare.
Myovant Sciences and Pfizer have published the results of the phase 3 SPIRIT 1 and SPIRIT 2 studies in The Lancet, assessing the investigational once-daily relugolix combination therapy in over ... Approximately 7.5 million premenopausal women in the US
The US Food and Drug Administration (FDA) has approved Myovant’s once-daily pill Orgovyx for prostate cancer. ... day,” said Lynn Seely, chief executive officer of Myovant Sciences.
Myovant Sciences will focus on delivering innovative therapies in the two areas, with former Medivation chief medical officer Lynn Seely appointed to lead the business. ... For its tie-up with Takeda, the Japanese firm has granted Myovant Sciences an
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
No results were found
We are Mtech Access, a global market access and health economics and outcomes research (HEOR) consultancy supporting top Pharmaceutical companies,...